三月 2026
protagonist-inc.com
显示 Similarweb 估计数据。
关联 GA4，公开验证您的网站指标
与您的成功同步
绑定 Google Analytics，验证您网站的流量及用户参与度指标
跳出率
40.76%
每次访问页数
2.36
平均访问时长
00:00:15
protagonist-inc.com的 10 大竞争对手
在 三月 2026 与 protagonist-inc.com 相似的前 10 名网站，按关键字流量、受众定位和市场重叠方面与 protagonist-inc.com 的关联性排名
Russ, GBS survivor and patient advocate COMMITTED TO HELPING PEOPLE WITH GBS LIVE THEIR BEST LIVES Annexon is working to deliver game-changing therapies for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. This includes our flagship investigational candidate for GBS, and a next wave of programs targeting Huntington’s Disease […]
跳出率
40.2%
每次访问页数
1.75
平均访问时长
00:00:20
After Adaptimmune has affinity-enhanced a TCR, the company can deliver it to patients through a robust and commercialized manufacturing process.
跳出率
43.07%
每次访问页数
1.78
平均访问时长
00:00:28
跳出率
42.45%
每次访问页数
1.86
平均访问时长
00:00:10
腸内細菌研究に基づいた医療・創薬を推進
- 公司
- - -
- 行业
- - -
跳出率
64.88%
每次访问页数
1.49
平均访问时长
00:01:56
Lirafugratinib is a highly selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors1,2
- 公司
- - -
- 行业
- - -
跳出率
39.21%
每次访问页数
1.62
平均访问时长
00:00:37
Dianthus Therapeutics is harnessing the power of selectivity to advance next-generation complement therapies.
- 行业
- 不适用
跳出率
36.7%
每次访问页数
2.22
平均访问时长
00:01:37
- 公司
- - -
- 行业
- - -
跳出率
47.09%
每次访问页数
1.69
平均访问时长
00:01:01
Basel, Switzerland, November 15, 2018. 09:00 CET BioSystems Technology, BioVersys and Voxcan join forces to establish IMPACT2 - an Innovative Multifaceted Platform for Antimicrobial Commercialisation Transformation Powered by Eurostars - a joint programme co-funded by EUREKA member countries and the European Union Horizon 2020 Framework Programme BioSystems Technology, BioVersys and…
- 公司
- - -
- 行业
- - -
跳出率
38.8%
每次访问页数
1.71
平均访问时长
00:00:34
A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used whenever possible to strengthen the evidence base for as many of our programs as possible.
- 公司
- - -
- 行业
- - -
跳出率
49.5%
每次访问页数
1.59
平均访问时长
00:00:21
Stay updated with the latest pharmaceutical industry news, trends, and insights. Explore in-depth analysis and expert reports. Visit us today!
- 公司
- - -
- 行业
- - -
跳出率
50.25%
每次访问页数
1.77
平均访问时长
00:00:39
protagonist-inc.com在 三月 2026 的前五名竞争对手是：annexonbio.com、adaptimmune.com、immunome.com、metagentx.com等。
根据 Similarweb 的月访问量数据，protagonist-inc.com 在 三月 2026 的头号竞争对手是 annexonbio.com。与 protagonist-inc.com 相似度排名第二的网站是 adaptimmune.com，排名第三的是 immunome.com。
在 三月 2026，metagentx.com 被评为与 protagonist-inc.com 相似度第四高的网站，elevartx.com 位居第五。
进入前十名榜单的其他五家竞争对手分别是 dianthustx.com、kalaristx.com、bioversys.com、amgenpipeline.com 和 pharmaceutical-technology.com。